Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Nivolumab + AVD in Frontline cHL
NCT05772624Phase 2Unknown
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Start
- Feb 2023
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in classic Hodgkin lymphoma (cHL), sponsored by Hospital Universitario Dr. Jose E. Gonzalez. Primary endpoint: General Response. Status: unknown.
02
Drugs
03
Conditions
classic Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT05772624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05772624.